The global in-vitro diagnostics enzymes market size is calculated at USD 2.49 billion in 2025 and is forecasted to reach around USD 4.34 billion by 2034, accelerating at a CAGR of 6.37% from 2025 to 2034. The North America in-vitro diagnostics enzymes market size surpassed USD 980 million in 2024 and is expanding at a CAGR of 6.39% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: In-vitro Diagnostics Enzymes Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. In-vitro Diagnostics Enzymes Market, by Enzyme Type
8.1.1. Proteases
8.1.1.1. Market Revenue and Forecast
8.1.2. Polymerase & Transcriptase
8.1.2.1. Market Revenue and Forecast
8.1.3. Ribonuclease
8.1.3.1. Market Revenue and Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Forecast
9.1. In-vitro Diagnostics Enzymes Market, by Disease Type
9.1.1. Infectious Disease
9.1.1.1. Market Revenue and Forecast
9.1.2. Diabetes
9.1.2.1. Market Revenue and Forecast
9.1.3. Oncology
9.1.3.1. Market Revenue and Forecast
9.1.4. Cardiology
9.1.4.1. Market Revenue and Forecast
9.1.5. Nephrology
9.1.5.1. Market Revenue and Forecast
9.1.6. Autoimmune diseases
9.1.6.1. Market Revenue and Forecast
9.1.7. Others
9.1.7.1. Market Revenue and Forecast
10.1. In-vitro Diagnostics Enzymes Market, by Technology Type
10.1.1. Histology Assays
10.1.1.1. Market Revenue and Forecast
10.1.2. Molecular Diagnostics
10.1.2.1. Market Revenue and Forecast
10.1.3. Clinical Chemistry
10.1.3.1. Market Revenue and Forecast
11.1. In-vitro Diagnostics Enzymes Market, by End-use
11.1.1. Pharma & Biotech
11.1.1.1. Market Revenue and Forecast
11.1.2. Hospital & Diagnostic Labs
11.1.2.1. Market Revenue and Forecast
11.1.3. Contract Research Organizations (CROs)
11.1.3.1. Market Revenue and Forecast
11.1.4. Academic Labs
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Enzyme Type
12.1.2. Market Revenue and Forecast, by Disease Type
12.1.3. Market Revenue and Forecast, by Technology Type
12.1.4. Market Revenue and Forecast, by End-use
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Enzyme Type
12.1.5.2. Market Revenue and Forecast, by Disease Type
12.1.5.3. Market Revenue and Forecast, by Technology Type
12.1.5.4. Market Revenue and Forecast, by End-use
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Enzyme Type
12.1.6.2. Market Revenue and Forecast, by Disease Type
12.1.6.3. Market Revenue and Forecast, by Technology Type
12.1.6.4. Market Revenue and Forecast, by End-use
12.2. Europe
12.2.1. Market Revenue and Forecast, by Enzyme Type
12.2.2. Market Revenue and Forecast, by Disease Type
12.2.3. Market Revenue and Forecast, by Technology Type
12.2.4. Market Revenue and Forecast, by End-use
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Enzyme Type
12.2.5.2. Market Revenue and Forecast, by Disease Type
12.2.5.3. Market Revenue and Forecast, by Technology Type
12.2.5.4. Market Revenue and Forecast, by End-use
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Enzyme Type
12.2.6.2. Market Revenue and Forecast, by Disease Type
12.2.6.3. Market Revenue and Forecast, by Technology Type
12.2.6.4. Market Revenue and Forecast, by End-use
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Enzyme Type
12.2.7.2. Market Revenue and Forecast, by Disease Type
12.2.7.3. Market Revenue and Forecast, by Technology Type
12.2.7.4. Market Revenue and Forecast, by End-use
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Enzyme Type
12.2.8.2. Market Revenue and Forecast, by Disease Type
12.2.8.3. Market Revenue and Forecast, by Technology Type
12.2.8.4. Market Revenue and Forecast, by End-use
12.3. APAC
12.3.1. Market Revenue and Forecast, by Enzyme Type
12.3.2. Market Revenue and Forecast, by Disease Type
12.3.3. Market Revenue and Forecast, by Technology Type
12.3.4. Market Revenue and Forecast, by End-use
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Enzyme Type
12.3.5.2. Market Revenue and Forecast, by Disease Type
12.3.5.3. Market Revenue and Forecast, by Technology Type
12.3.5.4. Market Revenue and Forecast, by End-use
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Enzyme Type
12.3.6.2. Market Revenue and Forecast, by Disease Type
12.3.6.3. Market Revenue and Forecast, by Technology Type
12.3.6.4. Market Revenue and Forecast, by End-use
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Enzyme Type
12.3.7.2. Market Revenue and Forecast, by Disease Type
12.3.7.3. Market Revenue and Forecast, by Technology Type
12.3.7.4. Market Revenue and Forecast, by End-use
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Enzyme Type
12.3.8.2. Market Revenue and Forecast, by Disease Type
12.3.8.3. Market Revenue and Forecast, by Technology Type
12.3.8.4. Market Revenue and Forecast, by End-use
12.4. MEA
12.4.1. Market Revenue and Forecast, by Enzyme Type
12.4.2. Market Revenue and Forecast, by Disease Type
12.4.3. Market Revenue and Forecast, by Technology Type
12.4.4. Market Revenue and Forecast, by End-use
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Enzyme Type
12.4.5.2. Market Revenue and Forecast, by Disease Type
12.4.5.3. Market Revenue and Forecast, by Technology Type
12.4.5.4. Market Revenue and Forecast, by End-use
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Enzyme Type
12.4.6.2. Market Revenue and Forecast, by Disease Type
12.4.6.3. Market Revenue and Forecast, by Technology Type
12.4.6.4. Market Revenue and Forecast, by End-use
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Enzyme Type
12.4.7.2. Market Revenue and Forecast, by Disease Type
12.4.7.3. Market Revenue and Forecast, by Technology Type
12.4.7.4. Market Revenue and Forecast, by End-use
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Enzyme Type
12.4.8.2. Market Revenue and Forecast, by Disease Type
12.4.8.3. Market Revenue and Forecast, by Technology Type
12.4.8.4. Market Revenue and Forecast, by End-use
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Enzyme Type
12.5.2. Market Revenue and Forecast, by Disease Type
12.5.3. Market Revenue and Forecast, by Technology Type
12.5.4. Market Revenue and Forecast, by End-use
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Enzyme Type
12.5.5.2. Market Revenue and Forecast, by Disease Type
12.5.5.3. Market Revenue and Forecast, by Technology Type
12.5.5.4. Market Revenue and Forecast, by End-use
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Enzyme Type
12.5.6.2. Market Revenue and Forecast, by Disease Type
12.5.6.3. Market Revenue and Forecast, by Technology Type
12.5.6.4. Market Revenue and Forecast, by End-use
13.1. Biocatalysts Ltd.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Amicogen
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Dyadic International
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. BBI Solutions
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Affymetrix
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. American Laboratories
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck KGaA
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Codexis, Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. F. Hoffmann-La Roche Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Amano Enzyme Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample